Avalon GloboCare shares surge 63.64% after-hours as FDA renews KetoAir registration and plans AI-driven B2B/B2C launch.

Avalon GloboCare Corp. surged 63.64% in after-hours trading following the announcement of the FDA registration renewal for its KetoAir™ breathalyzer and plans to launch the device in both B2B and B2C markets via its generative AI-powered Catch-Up™ platform in Q2 2026. The FDA renewal ensures continued regulatory compliance for the Class I medical device, which measures breath acetone to monitor ketogenic health. The company emphasized that the dual-market strategy, leveraging its AI-driven SaaS platform for marketing and engagement, represents a scalable and cost-efficient pathway to expand adoption. These developments underscore Avalon’s pivot toward integrating diagnostic hardware with digital marketing innovation, aligning with investor optimism around commercialization potential and operational diversification.